Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
infanrix-ipv+hib + prevenar
- Development stage
- Unknown
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination of two separate vaccines that are commonly administered together in childhood immunization schedules. **Infanrix-IPV+Hib** is a combined vaccine that protects against five diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), and Haemophilus influenzae type b (Hib) disease. It contains: - Diphtheria toxoid: not less than 30 International Units (IU) - Tetanus toxoid: not less than 40 International Units (IU) - Pertussis antigens: - Pertussis toxoid (PT): 25 micrograms - Filamentous haemagglutinin (FHA): 25 micrograms - Pertactin (PRN): 8 micrograms - Poliovirus (inactivated): - Type 1 (Mahoney strain): 40 D-antigen units - Type 2 (MEF-1 strain): 8 D-antigen units - Type 3 (Saukett strain): 32 D-antigen units - Haemophilus influenzae type b polysaccharide (PRP): 10 micrograms conjugated to tetanus toxoid as carrier protein (approximately 25 micrograms) The vaccine is manufactured by GlaxoSmithKline (GSK). **Prevenar (Pneumococcal Conjugate Vaccine)** is a pneumococcal conjugate vaccine that protects against Streptococcus pneumoniae infections. The search results indicate it contains 0.125 milligrams of aluminum as an adjuvant. These vaccines are often administered together as part of childhood immunization schedules, though as separate injections at different sites.
- Brand names
- Infanrix-IPV+Hib + Prevenar
02
Targets
CPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)
Beyond the preview
Go deeper on infanrix-ipv+hib + prevenar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on infanrix-ipv+hib + prevenar.